Pfizer to present new clinical data at ASH meeting

Pfizer will be attending the forthcoming annual meeting of the American Society of Hematology (ASH) in order to showcase the latest clinical data from its haematology pipeline.

During the conference in Atlanta, the company will presented updated chronic myeloid leukaemia data for its oral Abl and Src kinase inhibitor Bosulif, which was recently approved by the US Food and Drug Administration.

Several analyses of the compound will demonstrate how the therapy can help patients who do not respond to or are unable to tolerate conventional treatments, as well as those with drug-resistant cancers.

The company will also discuss new results for the developmental compound inotuzumab ozogamicin in acute lymphoblastic leukaemia and non-Hodgkin's lymphoma.

Dr Mace Rothenberg, senior vice-president of clinical development and medical affairs for Pfizer's oncology business unit, said: "This is a reflection of Pfizer's strong commitment to bringing innovative therapies to patients with haematologic cancers."

Earlier this week, the company completed its acquisition of NextWave Pharmaceuticals, a deal which will expand its portfolio of attention deficit hyperactivity disorder therapies.